Revolution Medicines(RVMD) - 2025 Q4 - Annual Results

Exhibit 99.1 Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress REDWOOD CITY, Calif., Feb 25, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter and full year ended December 31, 2025, and provided an update on corporate progress. "We made substantial clinical progress ...